References analysis of the Wikipedia article "Rak dróg żółciowych" in the Polish version

doi.org

S. Rizvi, G.J. Gores. Pathogenesis, diagnosis, and management of cholangiocarcinoma. „Gastroenterology”. 145 (6), s. 1215–1229, Dec 2013. DOI: 10.1053/j.gastro.2013.10.013. PMID: 24140396.

B. Blechacz, M. Komuta, T. Roskams, G.J. Gores. Clinical diagnosis and staging of cholangiocarcinoma. „Nat Rev Gastroenterol Hepatol”. 8 (9), s. 512–522, Sep 2011. DOI: 10.1038/nrgastro.2011.131. PMID: 21808282.

M.L. DeOliveira, S.C. Cunningham, J.L. Cameron, F. Kamangar i inni. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. „Ann Surg”. 245 (5), s. 755–762, May 2007. DOI: 10.1097/01.sla.0000251366.62632.d3. PMID: 17457168.

B.R. Blechacz, G.J. Gores. Cholangiocarcinoma. „Clin Liver Dis”. 12 (1), s. 131-150, ix, Feb 2008. DOI: 10.1016/j.cld.2007.11.003. PMID: 18242501.

S.A. Khan, M.B. Toledano, S.D. Taylor-Robinson. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. „HPB (Oxford)”. 10 (2), s. 77–82, 2008. DOI: 10.1080/13651820801992641. PMID: 18773060.

Y.A. Ghouri, I. Mian, B. Blechacz. Cancer review: Cholangiocarcinoma. „J Carcinog”. 14, s. 1, 2015. DOI: 10.4103/1477-3163.151940. PMID: 25788866.

H.R. Shin, J.K. Oh, E. Masuyer, M.P. Curado i inni. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. „Cancer Sci”. 101 (3), s. 579–585, Mar 2010. DOI: 10.1111/j.1349-7006.2009.01458.x. PMID: 20085587.

Maria Consiglia Bragazzi, Vincenzo Cardinale, Guido Carpino, Rosanna Venere i inni. Cholangiocarcinoma: Epidemiology and risk factors. „Transl Gastrointest Cancer”, 2012. DOI: 10.3978/j.issn.2224-4778.2011.11.04.

T. Patel. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. „Hepatology”. 33 (6), s. 1353–1357, Jun 2001. DOI: 10.1053/jhep.2001.25087. PMID: 11391522.

Y.H. Shaib, J.A. Davila, K. McGlynn, H.B. El-Serag. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. „J Hepatol”. 40 (3), s. 472–477, Mar 2004. DOI: 10.1016/j.jhep.2003.11.030. PMID: 15123362.

J. West, H. Wood, R.F. Logan, M. Quinn i inni. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. „Br J Cancer”. 94 (11), s. 1751–1758, Jun 2006. DOI: 10.1038/sj.bjc.6603127. PMID: 16736026.

T.M. Welzel, K.A. McGlynn, A.W. Hsing, T.R. O’Brien i inni. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. „J Natl Cancer Inst”. 98 (12), s. 873–875, Jun 2006. DOI: 10.1093/jnci/djj234. PMID: 16788161.

S. Saini. Imaging of the hepatobiliary tract. „N Engl J Med”. 336 (26), s. 1889–1894, Jun 1997. DOI: 10.1056/NEJM199706263362607. PMID: 9197218.

B.E. Van Beers. Diagnosis of cholangiocarcinoma. „HPB (Oxford)”. 10 (2), s. 87–93, 2008. DOI: 10.1080/13651820801992716. PMID: 18773062.

R. Materne, B.E. Van Beers, J.F. Gigot, J. Jamart i inni. Extrahepatic biliary obstruction: magnetic resonance imaging compared with endoscopic ultrasonography. „Endoscopy”. 32 (1), s. 3–9, Jan 2000. DOI: 10.1055/s-2000-86. PMID: 10691265.

H. Malhi, G.J. Gores. Cholangiocarcinoma: modern advances in understanding a deadly old disease. „J Hepatol”. 45 (6), s. 856–867, Dec 2006. DOI: 10.1016/j.jhep.2006.09.001. PMID: 17030071.

G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera i inni. Serum markers of intrahepatic cholangiocarcinoma. „Dis Markers”. 34 (4), s. 219–228, 2013. DOI: 10.3233/DMA-130964. PMID: 23396291.

G. Malaguarnera, M. Giordano, I. Paladina, A. Rando i inni. Markers of bile duct tumors. „World J Gastrointest Oncol”. 3 (4), s. 49–59, Apr 2011. DOI: 10.4251/wjgo.v3.i4.49. PMID: 21528090.

M. Shimada, Y. Yamashita, S. Aishima, K. Shirabe i inni. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. „Br J Surg”. 88 (11), s. 1463–1466, Nov 2001. DOI: 10.1046/j.0007-1323.2001.01879.x. PMID: 11683741.

S.B. Choi, K.S. Kim, J.Y. Choi, S.W. Park i inni. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. „Ann Surg Oncol”. 16 (11), s. 3048–3056, Nov 2009. DOI: 10.1245/s10434-009-0631-1. PMID: 19626372.

C.J. Clark, C.M. Wood-Wentz, K.M. Reid-Lombardo, M.L. Kendrick i inni. Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. „HPB (Oxford)”. 13 (9), s. 612–620, Sep 2011. DOI: 10.1111/j.1477-2574.2011.00340.x. PMID: 21843261.

Y. Morine, M. Shimada, T. Utsunomiya, S. Imura i inni. Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma. „Surg Today”. 42 (2), s. 147–151, Jan 2012. DOI: 10.1007/s00595-011-0057-9. PMID: 22124809.

J.H. Kim, H.J. Won, Y.M. Shin, K.A. Kim i inni. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. „AJR Am J Roentgenol”. 196 (2), s. W205-9, Feb 2011. DOI: 10.2214/AJR.10.4937. PMID: 21257864.

G. Carrafiello, D. Laganà, E. Cotta, M. Mangini i inni. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. „Cardiovasc Intervent Radiol”. 33 (4), s. 835–839, Aug 2010. DOI: 10.1007/s00270-010-9849-3. PMID: 20411389.

M.V. Kiefer, M. Albert, M. McNally, M. Robertson i inni. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. „Cancer”. 117 (7), s. 1498–1505, Apr 2011. DOI: 10.1002/cncr.25625. PMID: 21425151.

O. Hyder, J.W. Marsh, R. Salem, E.N. Petre i inni. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. „Ann Surg Oncol”. 20 (12), s. 3779–3786, Nov 2013. DOI: 10.1245/s10434-013-3127-y. PMID: 23846786.

J.B. Kuhlmann, W. Euringer, H.C. Spangenberg, M. Breidert i inni. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. „Eur J Gastroenterol Hepatol”. 24 (4), s. 437–443, Apr 2012. DOI: 10.1097/MEG.0b013e3283502241. PMID: 22261548.

S.C. Schiffman, T. Metzger, G. Dubel, T. Andrasina i inni. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. „Ann Surg Oncol”. 18 (2), s. 431–438, Feb 2011. DOI: 10.1245/s10434-010-1333-4. PMID: 20862554.

S.M. Ibrahim, M.F. Mulcahy, R.J. Lewandowski, K.T. Sato i inni. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. „Cancer”. 113 (8), s. 2119–2128, Oct 2008. DOI: 10.1002/cncr.23818. PMID: 18759346.

S. Mouli, K. Memon, T. Baker, A.B. Benson i inni. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. „J Vasc Interv Radiol”. 24 (8), s. 1227–1234, Aug 2013. DOI: 10.1016/j.jvir.2013.02.031. PMID: 23602420.

R.T. Hoffmann, P.M. Paprottka, A. Schön, F. Bamberg i inni. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. „Cardiovasc Intervent Radiol”. 35 (1), s. 105–116, Feb 2012. DOI: 10.1007/s00270-011-0142-x. PMID: 21431970.

K. Shitara, I. Ikami, M. Munakata, O. Muto i inni. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. „Clin Oncol (R Coll Radiol)”. 20 (3), s. 241–246, Apr 2008. DOI: 10.1016/j.clon.2007.12.007. PMID: 18222071.

Y. Inaba, Y. Arai, H. Yamaura, Y. Sato i inni. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). „Am J Clin Oncol”. 34 (1), s. 58–62, Feb 2011. DOI: 10.1097/COC.0b013e3181d2709a. PMID: 20177362.

N.E. Kemeny, L. Schwartz, M. Gönen, A. Yopp i inni. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?. „Oncology”. 80 (3–4), s. 153–159, 2011. DOI: 10.1159/000324704. PMID: 21677464.

N. Akamatsu, Y. Sugawara, D. Hashimoto. Surgical strategy for bile duct cancer: Advances and current limitations. „World J Clin Oncol”. 2 (2), s. 94–107, Feb 2011. DOI: 10.5306/wjco.v2.i2.94. PMID: 21603318.

K.C. Soares, I. Kamel, D.P. Cosgrove, J.M. Herman i inni. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. „Hepatobiliary Surg Nutr”. 3 (1), s. 18–34, Feb 2014. DOI: 10.3978/j.issn.2304-3881.2014.02.05. PMID: 24696835.

E.S. Glazer, P. Liu, E.K. Abdalla, J.N. Vauthey i inni. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. „J Gastrointest Surg”. 16 (9), s. 1666–1671, Sep 2012. DOI: 10.1007/s11605-012-1935-1. PMID: 22777053.

A.M. Horgan, E. Amir, T. Walter, J.J. Knox. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. „J Clin Oncol”. 30 (16), s. 1934–1940, Jun 2012. DOI: 10.1200/JCO.2011.40.5381. PMID: 22529261.

T. Takada, H. Amano, H. Yasuda, Y. Nimura i inni. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. „Cancer”. 95 (8), s. 1685–1695, Oct 2002. DOI: 10.1002/cncr.10831. PMID: 12365016.

T.H. Kim, S.S. Han, S.J. Park, W.J. Lee i inni. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. „Int J Radiat Oncol Biol Phys”. 81 (5), s. e853-9, Dec 2011. DOI: 10.1016/j.ijrobp.2010.12.019. PMID: 21497455.

K.H. Lim, D.Y. Oh, E.K. Chie, J.Y. Jang i inni. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. „BMC Cancer”. 9, s. 345, 2009. DOI: 10.1186/1471-2407-9-345. PMID: 19781103.

Y. Borghero, C.H. Crane, J. Szklaruk, M. Oyarzo i inni. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. „Ann Surg Oncol”. 15 (11), s. 3147–3156, Nov 2008. DOI: 10.1245/s10434-008-9998-7. PMID: 18754070.

J.H. Park, E.K. Choi, S.D. Ahn, S.W. Lee i inni. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. „Int J Radiat Oncol Biol Phys”. 79 (3), s. 696–704, Mar 2011. DOI: 10.1016/j.ijrobp.2009.12.031. PMID: 20510541.

A. Sharma, A.D. Dwary, B.K. Mohanti, S.V. Deo i inni. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. „J Clin Oncol”. 28 (30), s. 4581–4586, Oct 2010. DOI: 10.1200/JCO.2010.29.3605. PMID: 20855823.

F. Eckel, R.M. Schmid. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. „Br J Cancer”. 96 (6), s. 896–902, Mar 2007. DOI: 10.1038/sj.bjc.6603648. PMID: 17325704.

J. Valle, H. Wasan, D.H. Palmer, D. Cunningham i inni. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. „N Engl J Med”. 362 (14), s. 1273–1281, Apr 2010. DOI: 10.1056/NEJMoa0908721. PMID: 20375404.

T. Okusaka, K. Nakachi, A. Fukutomi, N. Mizuno i inni. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. „Br J Cancer”. 103 (4), s. 469–474, Aug 2010. DOI: 10.1038/sj.bjc.6605779. PMID: 20628385.

M. Ducreux, E. Van Cutsem, J.L. Van Laethem, T.M. Gress i inni. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. „Eur J Cancer”. 41 (3), s. 398–403, Feb 2005. DOI: 10.1016/j.ejca.2004.10.026. PMID: 15691639.

J. Park, M.H. Kim, K.P. Kim, do H. Park i inni. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. „Gut Liver”. 3 (4), s. 298–305, Dec 2009. DOI: 10.5009/gnl.2009.3.4.298. PMID: 20431764.

nih.gov

ncbi.nlm.nih.gov

S.H. Landis, T. Murray, S. Bolden, P.A. Wingo. Cancer statistics, 1998. „CA Cancer J Clin”. 48 (1). s. 6–29. PMID: 9449931.

S. Rizvi, G.J. Gores. Pathogenesis, diagnosis, and management of cholangiocarcinoma. „Gastroenterology”. 145 (6), s. 1215–1229, Dec 2013. DOI: 10.1053/j.gastro.2013.10.013. PMID: 24140396.

H.A. Pitt, W.C. Dooley, C.J. Yeo, J.L. Cameron. Malignancies of the biliary tree. „Curr Probl Surg”. 32 (1), s. 1–90, Jan 1995. PMID: 7528652.

Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. „Ann Surg”. 215, s. 31–38, 1992. PMID: 1309988.

B.R. Blechacz, G.J. Gores. Cholangiocarcinoma. „Clin Liver Dis”. 12 (1), s. 131-150, ix, Feb 2008. DOI: 10.1016/j.cld.2007.11.003. PMID: 18242501.

Steven A.= Curley: Bile Duct Cancer. W: Donald W. Kufe, Raphael E. Pollock, Ralph R. Weichselbaum, Robert C. Bast, Ted S. Gansler: Holland-Frei Cancer Medicine, 6th edition. BC Decker, 2003. ISBN 1-55009-213-8.

Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, Bethony JM, Loukas A, Brindley PJ. Liver Fluke Induces Cholangiocarcinoma. „PLoS Med”. 4. 7, s. e201, 2007. PMID: 17622191.

Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. „Br J Surg”. 83, s. 1062–1064, 1996. PMID: 8869303.

Lipsett P, Pitt H, Colombani P, Boitnott J, Cameron J. Choledochal cyst disease. A changing pattern of presentation. „Ann Surg”. 220. 5, s. 644–652, 1994. PMID: 7979612.

Dayton M, Longmire W, Tompkins R. Caroli’s Disease: a premalignant condition?. „Am J Surg”. 145. 1, s. 41–48, 1983. PMID: 6295196.

Chow WH, McLaughlin JK, Menck HR, Mack TM. Risk factors for extrahepatic bile duct cancers: Los Angeles County, California (USA). „Cancer Causes Control”. 5, s. 267–272, 1994. PMID: 8061176.

Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. „Hepatology”. 27, s. 311–316, 1998. PMID: 9462625.

Callea F, Sergi C, Fabbretti G, Brisigotti M, Cozzutto C, Medicina D. Precancerous lesions of the biliary tree. „J Surg Oncol Suppl”. 3, s. 131–133, 1993. PMID: 8389160.

Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma?. „Cancer”. 88. 12, s. 2668–2676, 2000. PMID: 10870048.

Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. „Gut”. 38, s. 610–615, 1996. PMID: 8707097.

Hocqueloux L, Gervais A. Cholangiocarcinoma and AIDS-related sclerosing cholangitis. „Ann Intern Med”. 132. 12, s. 1006–1007, 2000. PMID: 10858162.

de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. „New England Journal of Medicine”. 341, s. 1368–1378, 1999. PMID: 10536130.

Shaib Y, El-Serag H, Davila J, Morgan R, McGlynn K. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. „Gastroenterology”. 128. 3, s. 620–626, 2005. PMID: 15765398.

Mecklin JP, Jarvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. „Cancer”. 69. 5, s. 1112–1114, 1992. PMID: 1310886.

Vernez M, Hutter P, Monnerat C, Halkic N, Gugerli O, Bouzourene H. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. „Fam Cancer”. 6. 1, s. 141–145, 2007. PMID: 17051350.

Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. „Cancer Epidemiol Biomarkers Prev”. 2. 6, s. 537–544, 1993. PMID: 826877.

S.A. Khan, S.D. Taylor-Robinson, M.B. Toledano, A. Beck i inni. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. „J Hepatol”. 37 (6), s. 806–813, Dec 2002. PMID: 12445422.

Y.A. Ghouri, I. Mian, B. Blechacz. Cancer review: Cholangiocarcinoma. „J Carcinog”. 14, s. 1, 2015. DOI: 10.4103/1477-3163.151940. PMID: 25788866.

D.E. Henson, J. Albores-Saavedra, D. Corle. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. „Cancer”. 70 (6), s. 1498–1501, Sep 1992. PMID: 1516001.

T. Patel. Worldwide trends in mortality from biliary tract malignancies. „BMC Cancer”. 2, s. 10, May 2002. PMID: 11991810.

Y.H. Shaib, H.B. El-Serag, J.A. Davila, R. Morgan i inni. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. „Gastroenterology”. 128 (3), s. 620–626, Mar 2005. PMID: 15765398.

Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. „Oncogene”. 25 (27), s. 3818–3822, 2006. PMID: 16799623.

Liu C, Wang J, Ou Q. Possible stem cell origin of human cholangiocarcinoma. „World J Gastroenterol”. 10 (22), s. 3374–3376, 2004. PMID: 15484322.

Sell S, Dunsford H. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. „Am J Pathol”. 134 (6), s. 1347–1363, 1989. PMID: 2474256.

Sirica A. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. „Hepatology”. 41 (1), s. 5–15, 2005. PMID: 15690474.

Holzinger F, Z’graggen K, Büchler M. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. „Ann Oncol”. 10 Suppl 4. s. 122–126. PMID: 10436802.

Gores G. Cholangiocarcinoma: current concepts and insights. „Hepatology”. 37 (5), s. 961–969, 2003. PMID: 12717374.

Suto T, Sugai T, Nakamura S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. „Cancer”. 82, s. 86–95, 1998. PMID: 9428483.

Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. „Hum Pathol”. 29, s. 175–180, 1998. PMID: 9490278.

Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. „J Surg Oncol”. 68, s. 187–192, 1998. PMID: 9701213.

Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development. „Hum Pathol”. 20, s. 1163–1168, 1989. PMID: 2574140.

S. Saini. Imaging of the hepatobiliary tract. „N Engl J Med”. 336 (26), s. 1889–1894, Jun 1997. DOI: 10.1056/NEJM199706263362607. PMID: 9197218.

M.P. Sharma, V. Ahuja. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician’s perspective. „Trop Gastroenterol”. 20 (4). s. 167–169. PMID: 10769604.

B.E. Van Beers. Diagnosis of cholangiocarcinoma. „HPB (Oxford)”. 10 (2), s. 87–93, 2008. DOI: 10.1080/13651820801992716. PMID: 18773062.

J. Romagnuolo, M. Bardou, E. Rahme, L. Joseph i inni. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. „Ann Intern Med”. 139 (7), s. 547–557, Oct 2003. PMID: 14530225.

A. Weber, R.M. Schmid, C. Prinz. Diagnostic approaches for cholangiocarcinoma. „World J Gastroenterol”. 14 (26), s. 4131–4136, Jul 2008. PMID: 18636656.

S.M. Weber, R.P. DeMatteo, Y. Fong, L.H. Blumgart i inni. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. „Ann Surg”. 235 (3), s. 392–399, Mar 2002. PMID: 11882761.

M.P. Callery, S.M. Strasberg, G.M. Doherty, N.J. Soper i inni. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. „J Am Coll Surg”. 185 (1), s. 33–39, Jul 1997. PMID: 9208958.

H. Malhi, G.J. Gores. Cholangiocarcinoma: modern advances in understanding a deadly old disease. „J Hepatol”. 45 (6), s. 856–867, Dec 2006. DOI: 10.1016/j.jhep.2006.09.001. PMID: 17030071.

X.L. Qin, Z.R. Wang, J.S. Shi, M. Lu i inni. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. „World J Gastroenterol”. 10 (3), s. 427–432, Feb 2004. PMID: 14760772.

B. Juntermanns, S. Radunz, M. Heuer, S. Hertel i inni. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. „Eur J Med Res”. 15 (8), s. 357–361, Aug 2010. PMID: 20947473.

W.F. Shen, W. Zhong, F. Xu, T. Kan i inni. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. „World J Gastroenterol”. 15 (47), s. 5976–5982, Dec 2009. PMID: 20014463.

G. Malaguarnera, M. Giordano, I. Paladina, A. Rando i inni. Markers of bile duct tumors. „World J Gastrointest Oncol”. 3 (4), s. 49–59, Apr 2011. DOI: 10.4251/wjgo.v3.i4.49. PMID: 21528090.

J.K. Ramage, A. Donaghy, J.M. Farrant, R. Iorns i inni. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. „Gastroenterology”. 108 (3), s. 865–869, Mar 1995. PMID: 7875490.

G. Poggi, P. Quaretti, C. Minoia, G. Bernardo i inni. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. „Anticancer Res”. 28 (6B). s. 3835–3842. PMID: 19192637.

B. Glimelius, K. Hoffman, P.O. Sjödén, G. Jacobsson i inni. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. „Ann Oncol”. 7 (6), s. 593–600, Aug 1996. PMID: 8879373.

G.V. Kornek, B. Schuell, F. Laengle, T. Gruenberger i inni. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. „Ann Oncol”. 15 (3), s. 478–483, Mar 2004. PMID: 14998852.

F. Mihalache, M. Tantau, B. Diaconu, M. Acalovschi. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. „J Gastrointestin Liver Dis”. 19 (3), s. 285–290, Sep 2010. PMID: 20922193.

pubmedcentral.nih.gov

Rak dróg żółciowych (Polish Wikipedia)

archive.ph

bmj.com

gut.bmj.com

cancer.org

czytelniamedyczna.pl

doi.org

google.pl

books.google.pl

mp.pl

nih.gov

ncbi.nlm.nih.gov

pubmedcentral.nih.gov

termedia.pl

upenn.edu

med.upenn.edu

web.archive.org

wiley.com

onlinelibrary.wiley.com

zalecenia.med.pl

onkologia.zalecenia.med.pl